Home / Market News / $CVS
benzinga Corporate Catalyst Impact 55/100 ● negative

Leerink Partners Maintains Outperform on CVS Health, Lowers Price Target to $112

Oct 12, 2026, 12:59 PM UTC · Primary ticker $CVS

Leerink Partners analyst Michael Cherny reiterated an Outperform rating on CVS Health but reduced the price target from $119 to $112. This indicates a slightly less optimistic outlook on the stock's near-term valuation, though the underlying positive sentiment remains.

Leerink Partners analyst Michael Cherny maintained an 'Outperform' rating on CVS Health, signaling continued confidence in the company's long-term prospects. However, the reduction of the price target from $119 to $112 suggests a recalibration of near-term valuation expectations, possibly due to broader market conditions, competitive pressures, or specific company-related factors not detailed in this brief filing. This move primarily affects CVS Health investors, who might see a slight downward pressure on the stock in the short term as the market digests the revised target. Long-term implications are less clear, as the 'Outperform' rating still implies potential for growth. For traders, this presents a minor bearish signal for CVS, potentially leading to short-term selling pressure or a re-evaluation of entry points.

$CVS negative Price target lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.